Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

Conditions: Advanced Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Bright White Light Therapy, Combination Drug Therapy, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older · Male only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions: Sodium Fusidate, Placebo; Drug
Lead sponsor: Aceragen; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 25
States / cities: Gainesville, Florida • Orlando, Florida • Pensacola, Florida + 22 more

Conditions: Post Menopausal
Interventions: videodance, Brisk Walking, delayed entry control; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Anxiety Disorder
Interventions: Thinking Skills for Work Program, Supported Employment; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Manchester, New Hampshire

Conditions: Diabetes Mellitus, Type 2
Interventions: high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 112
States / cities: Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more

Conditions: Adult Attention Deficit Hyperactivity Disorder
Interventions: SEP-225289, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Encino, California • Garden Grove, California • Irvine, California + 28 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi, combination therapy with MEKi.; Other · Drug
Lead sponsor: Mandana Kamgar, MD; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Feeding Tube, Children With Medical Complexity, Tracheostomy, Feeding Disorder, Infancy or Early Childhood
Interventions: Tube weaning therapy intervention, Feeding Group; Other
Lead sponsor: University of Chicago; Other
Eligibility: Up to 3 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clinical High Risk for Psychosis (CHR)
Interventions: CBT Skills Group for CHR Youth, Individual CBT sessions, CBT Skills Group for Families; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 14 Years to 25 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser; Drug · Behavioral · Procedure
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 56
States / cities: Artesia, California • Beverly Hills, California • Irvine, California + 46 more

Conditions: Human Immunodeficiency Virus
Interventions: 10-1074-LS, 3BNC117-LS; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 32
States / cities: Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more

Conditions: Soft Tissue Sarcoma
Interventions: Olaratumab, Gemcitabine, Docetaxel, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 16 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 21
States / cities: Santa Monica, California • Aurora, Colorado • Jacksonville, Florida + 17 more

Conditions: Hyperlipidemia
Interventions: SLx-4090, Placebo, Statin; Drug · Other
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more

Conditions: Prostate Adenocarcinoma
Interventions: Q-Urol, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Schizophrenia
Interventions: Linagliptin; Drug
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Transplant; Failure, Kidney
Interventions: Alemtuzumab, Daclizumab, Thymoglobulin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Parkinson's Disease
Interventions: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),; Drug
Lead sponsor: Pharma Two B Ltd.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Venetoclax, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Tobacco Cigarette Smoking
Interventions: Smartphone-based intervention messages; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 30 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions: Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin; Dietary Supplement · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Binocular Vision Disorder, Refractive Errors, Cataract
Interventions: cataract surgery, Corneal refractive surgery; Procedure
Lead sponsor: Salus University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Elkins Park, Pennsylvania

Conditions: Heart Diseases
Interventions: Lidocaine, Unrestricted Fentanyl, Ketamine, Precedex, Duramorph; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Adherence and Health Effects of Video Dance in Postmenopausal Women

Thinking Skills for Work in Severe Mental Illness

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Adult Attention Deficit Hyperactivity Disorder

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Let's E.A.T.! (Eating With Assistive Technology): An Intervention to Support Children With Feeding Tubes and Tracheostomies

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Testing the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Binocular Vision Anomalies After Cataract and Refractive Surgery

Multimodal Analgesia in Cardiac Surgery (Pilot Study)